Michael Stowasser1, Martin Wolley2, Aihua Wu2, Richard D Gordon2, Julia Schewe3, Gabriel Stölting3, Ute I Scholl3. 1. Endocrine Hypertension Research Centre, University of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, 4102, Australia. m.stowasser@uq.edu.au. 2. Endocrine Hypertension Research Centre, University of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, 4102, Australia. 3. Department of Nephrology and Medical Intensive Care, BCRT, Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.
Abstract
PURPOSE OF REVIEW: The application of advanced genetic techniques has recently begun to unravel the genetic basis for familial primary aldosteronism type 2 (FH-II). RECENT FINDINGS: Whole-exome sequencing in a large family with FH-II revealed a shared rare damaging heterozygous variant in CLCN2 (chr.3: g.184075850C>T, p.Arg172Gln) in three severely affected members. The gene encodes a chloride channel, ClC-2. A cohort of 80 unrelated individuals diagnosed with early-onset primary aldosteronism was also examined for CLCN2 mutations finding three further occurrences of p.Arg172Gln mutations and four single cases of other potentially damaging heterozygous mutations for an overall prevalence of 9.9%. A concurrent report also found a different CLCN2 mutation (p.Gly24Asp) in a single severely affected patient from a cohort of 12 with early-onset PA for a prevalence of 8.3%. Cases of primary aldosteronism associated with CLCN2 mutations appear to be bilateral and respond well to medical treatment. In the adrenal, ClC-2 has been demonstrated to localize predominantly to the zona glomerulosa (ZG), and functional analysis suggests that mutations in ClC-2 predispose ZG cells to depolarization, thus leading to calcium influx via activation of voltage-gated calcium channels and increased aldosterone production. Germline CLCN2 mutations appear to account for a substantial proportion of early-onset primary aldosteronism cases, and genetic testing for mutations in this gene should be considered in appropriate cases.
PURPOSE OF REVIEW: The application of advanced genetic techniques has recently begun to unravel the genetic basis for familial primary aldosteronism type 2 (FH-II). RECENT FINDINGS: Whole-exome sequencing in a large family with FH-II revealed a shared rare damaging heterozygous variant in CLCN2 (chr.3: g.184075850C>T, p.Arg172Gln) in three severely affected members. The gene encodes a chloride channel, ClC-2. A cohort of 80 unrelated individuals diagnosed with early-onset primary aldosteronism was also examined for CLCN2 mutations finding three further occurrences of p.Arg172Gln mutations and four single cases of other potentially damaging heterozygous mutations for an overall prevalence of 9.9%. A concurrent report also found a different CLCN2 mutation (p.Gly24Asp) in a single severely affected patient from a cohort of 12 with early-onset PA for a prevalence of 8.3%. Cases of primary aldosteronism associated with CLCN2 mutations appear to be bilateral and respond well to medical treatment. In the adrenal, ClC-2 has been demonstrated to localize predominantly to the zona glomerulosa (ZG), and functional analysis suggests that mutations in ClC-2 predispose ZG cells to depolarization, thus leading to calcium influx via activation of voltage-gated calcium channels and increased aldosterone production. Germline CLCN2 mutations appear to account for a substantial proportion of early-onset primary aldosteronism cases, and genetic testing for mutations in this gene should be considered in appropriate cases.
Authors: Leandro Zúñiga; María Isabel Niemeyer; Diego Varela; Marcelo Catalán; L Pablo Cid; Francisco V Sepúlveda Journal: J Physiol Date: 2004-01-14 Impact factor: 5.182
Authors: Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton Journal: Science Date: 2011-02-11 Impact factor: 47.728
Authors: Kazutaka Nanba; Kei Omata; Tobias Else; Peter C C Beck; Aya T Nanba; Adina F Turcu; Barbra S Miller; Thomas J Giordano; Scott A Tomlins; William E Rainey Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Ute I Scholl; Gerald Goh; Gabriel Stölting; Regina Campos de Oliveira; Murim Choi; John D Overton; Annabelle L Fonseca; Reju Korah; Lee F Starker; John W Kunstman; Manju L Prasad; Erum A Hartung; Nelly Mauras; Matthew R Benson; Tammy Brady; Jay R Shapiro; Erin Loring; Carol Nelson-Williams; Steven K Libutti; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Peyman Björklund; Tobias Carling; Christoph Fahlke; Patricia Hidalgo; Richard P Lifton Journal: Nat Genet Date: 2013-08-04 Impact factor: 38.330